Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early Detection.
Efstathia LiatsouIoanna TatouliAndreas MpozikasMaria-Markella PavlouHariklia GakiopoulouIoannis Ntanasis-StathopoulosMaria GavriatopoulouSofoklis KontogiannisMeletios- Athanasios DimopoulosPublished in: Journal of clinical medicine (2023)
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that has been widely used for the treatment of patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. However, in the HBV monoinfection scenario, only five cases of TDF-associated Fanconi syndrome have been reported thus far, two of them providing a confirmatory kidney biopsy. Here, we describe the case of a 68-year-old woman with chronic hepatitis B (CHB) who developed TDF-induced Fanconi syndrome that reverted after TDF withdrawal from tenofovir alafenamide. Though the overall risk of TDF-associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular functions should be monitored in patients exposed to TDF.
Keyphrases
- hepatitis b virus
- human immunodeficiency virus
- antiretroviral therapy
- liver failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- hiv infected
- hepatitis c virus
- chronic kidney disease
- hiv positive
- prognostic factors
- peritoneal dialysis
- oxidative stress
- patient reported outcomes
- diabetic rats
- early onset
- south africa
- extracorporeal membrane oxygenation
- diabetic nephropathy
- acute respiratory distress syndrome
- endothelial cells
- hiv testing
- mechanical ventilation
- patient reported